<DOC>
	<DOCNO>NCT02475551</DOCNO>
	<brief_summary>This study ass safety efficacy IdeS transplantation set . Each patient receive one dose IdeS . If crossmatch test negative time transplantation , patient transplant kidney decease living donor . The start dose 0.25 mg/kg BW , give single intravenous infusion prior surgery .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Efficacy PK IdeS Kidney Transplantation</brief_title>
	<detailed_description>This study ass safety efficacy IgG degrade cysteine protease IdeS transplantation set . Patients DSAs treat IdeS prior transplantation . Each patient receive one dose IdeS . If crossmatch test negative IdeS treatment , patient transplant kidney decease living donor . Two four dose group plan . Each group contain 2 patient possibility extend group 4 patient per group require safety and/or efficacy evaluation . The start dose 0.25 mg/kg BW , give single intravenous infusion prior surgery possibility increase dose high dose group .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients diagnose CKD dialysis preform antiHLA antibody ( nonDSA , DSA ) , negative TCDC CXM least one antibody MFI &gt; 3000 Prior malignancy within 2 year exclude adequately treat basal cell squamous cell skin cancer , cervical carcinoma situ prostate cancer Gleason &lt; 6 prostatespecific antigen ( PSA ) &lt; 10 ng/mL . Any positive result screen serum hepatitis B surface antigen , hepatitis C antibody human immunodeficiency virus ( HIV Clinical sign ongoing infectious disease . Severe condition require treatment close monitoring , e.g . cardiac failure &gt; New York Heart Association ( NYHA ) grade 3 , unstable coronary disease oxygen dependent chronic obstructive pulmonary disease ( COPD ) History clinically significant disease disorder , opinion investigator , may either put patient increase risk participation study , influence result patient 's ability participate study Hypogammaglobulinemia define value Ptotal IgG le 3 g/L History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class IdeS ( e. g streptokinase and/or staphylokinase ) Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within 4 month first administration investigational product study . Patients consent screen dose previous study exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>